

**Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: Densitometric, histomorphometric and microtomographic studies.**

Hélène Libouban, Stéphane Blouin, Marie-Françoise Moreau, Michel Félix Baslé, Maurice Audran, Daniel Chappard

► **To cite this version:**

Hélène Libouban, Stéphane Blouin, Marie-Françoise Moreau, Michel Félix Baslé, Maurice Audran, et al.. Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: Densitometric, histomorphometric and microtomographic studies.: Bone loss due to orchidectomy and localized disuse.. Micron, Elsevier, 2008, 39 (7), pp.998-1007. 10.1016/j.micron.2007.09.006 . inserm-00259382

**HAL Id: inserm-00259382**

**<https://www.hal.inserm.fr/inserm-00259382>**

Submitted on 27 Feb 2008

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**EARLY PREVENTIVE EFFECTS OF RISEDRONATE IN A RAT  
MODEL WITH MASSIVE BONE LOSS DUE TO ORCHIDECTOMY AND  
LOCALIZED DISUSE.**

**Hélène LIBOUBAN <sup>1\*</sup>, Stéphane BLOUIN <sup>1\*</sup>, Marie-Françoise MOREAU <sup>1</sup>,  
Michel Félix BASLE <sup>1</sup>, Maurice AUDRAN <sup>1,2</sup>, Daniel CHAPPARD <sup>1</sup>**

<sup>1</sup> INSERM EMI 0335-LHEA, Faculté de Médecine, 49045 ANGERS Cédex - FRANCE

<sup>2</sup> Service de Rhumatologie, CHU d'Angers, 49033 ANGERS Cédex - FRANCE

\* Both authors contributed equally to this work

**Funding sources:** “Pays de la Loire” - Axe Biomatériaux and INSERM

**Short running title:** Bone loss due to orchidectomy and localized disuse.

**Author's email address:** [helene.libouban@univ-angers.fr](mailto:helene.libouban@univ-angers.fr)  
[stephane.blouin@etud.univ-angers.fr](mailto:stephane.blouin@etud.univ-angers.fr)  
[mfmoreau@med.univ-angers.fr](mailto:mfmoreau@med.univ-angers.fr)  
[michel.basle@univ-angers.fr](mailto:michel.basle@univ-angers.fr)  
[maaudran@chu-angers.fr](mailto:maaudran@chu-angers.fr)  
[daniel.chappard@univ-angers.fr](mailto:daniel.chappard@univ-angers.fr)

**Corresponding author:** **Daniel CHAPPARD, M.D., Ph.D.**  
INSERM EMI 0335 - LHEA Faculté de Médecine  
49045 ANGERS Cédex – France  
Tel: +33 241 73 58 65 / Fax: +33 241 73 58 86  
[daniel.chappard@univ-angers.fr](mailto:daniel.chappard@univ-angers.fr)

**Number of words in abstract :** 342 (including microabstarct)

**Number of words in manuscript :** 6087

**Number of Figures :** 5 in black and white

## ABSTRACT

---

**Alterations on lean, fat mass, bone mass and architecture were maximized on the paralysed side of a model combining orchidectomy and hindlimb paralysis induced by botulinum neurotoxin. Risedronate have protective effects on trabecular bone but failed to preserve cortical bone on the paralysed side.**

**Introduction:** Orchidectomy (ORX) in rat and unilateral hindlimb paralysis induced by botulinum neurotoxin (BTX) are respectively suitable models for hypogonadism and disuse induced osteoporosis. ORX and BTX models were combined to see if their effects were cumulative and if bone loss could be prevented by risedronate or testosterone.

**Materials and Methods:** 4 groups of 12 rats were examined for 1 month: SHAM operated; ORX and paralyzed in right hindlimb; ORX+BTX+risedronate (5 $\mu$ g/kg/d), ORX+BTX+testosterone (30 $\mu$ g/kg/day). Modifications of bone, lean and fat mass were examined by DXA on whole body, regional left and right hindlimbs and on excised tibia and femur. BV/TV, Tb.Th, Tb.N, Tb.Sp and microarchitectural parameters were assessed by histomorphometry. Trabecular 3D and cortical 2D measurements were assessed by X-ray microtomography.

**Results:** Whole body BMC and lean mass were decreased in ORX-BTX and respectively preserved by risedronate but not by testosterone, by testosterone but not by risedronate. On paralysed side, decrease of lean mass was maximized and could not be prevented by testosterone. In right tibial metaphysis, bone loss was maximized: -33.5% BMC vs. -11.2% on left side. BMC is completely preserved by risedronate. BV/TV and Tb.N decreased and Tb.Sp increased on both sides whereas Tb.Th was significantly lower only on the paralyzed side. Alterations of 2D and 3D architecture were significantly highest on the paralysed side. Risedronate preserved trabecular volume and architecture but not trabecular thickness.

Testosterone was less effective except for trabecular thickness. Cortical area, thickness and cross-sectional moment of inertia were altered with maximum changes on the paralysed side. Risedronate preserved cortical bone on left side but not on paralysed side. Testosterone was ineffective in preserving cortical bone.

**Conclusions:** The combined model appears suitable to evaluate pharmacological compounds since bone loss occurs rapidly. Risedronate have early and protective effects on trabecular bone mass and bone architecture.

**KEY WORDS:**

---

Osteoporosis

Orchidectomy

Disuse

Risedronate

Bone histomorphometry

MicroCT

## INTRODUCTION

---

Sex hormones are recognized as important factors in the maintenance of bone mass and architecture. An increased bone-remodeling rate is observed in women after menopause or surgical castration. In men, the prevalence of osteoporosis has often been underestimated. Epidemiological studies have shown that about 30% of hip and 20% of vertebral fractures occur in men.<sup>(1,2)</sup> American studies have estimated that the lifetime risk of hip fracture in 50 year-old white men is about 6% and the risk of vertebral fracture about 5%.<sup>(3,4)</sup> In the aging man, a decrease in blood testosterone levels or an increase in its complexing protein (Sex Hormon Binding Globulin – SHBG) have been found to occur in a number of patients.<sup>(5,6)</sup> Reduced testosterone level is associated with modifications of the body composition and fat, lean and body masses have been found to be altered.<sup>(7-9)</sup> These changes are similar to those described in patients with primary or acquired hypogonadism and appear highly correlated with androgen levels.<sup>(10-12)</sup> Bone mineral density was reported to be correlated with fat body mass.<sup>(13,14)</sup> Other studies have found that both fat and lean body mass have important effects on bone mass, depending on the bone parameter considered, the skeletal site measured and the hormonal status.<sup>(15-17)</sup> The mechanisms governing the fat and lean masses and their relationships to the decrease in bone mass with age and gender are still unclear.<sup>(18)</sup> Muscular activity is well known to exert positive effects on bone mass<sup>(19,20)</sup> and hormones released by adipocytes (leptin and adiponectin) are also known to control bone mass.<sup>(21)</sup>

Generalized bone loss, developed in the course of disuse, is a well recognized complication after para or tetraplegia in human.<sup>(22)</sup> A localized loss of bone is also documented in patients with regional disuse after fracture<sup>(23)</sup>, unilateral amputation<sup>(24)</sup>, stroke or poliomyelitis<sup>(25)</sup> and reduced physical activity<sup>(26,27)</sup>. However, in men, other risk factors are commonly observed and intricaded in the pathogenesis of osteoporosis

(smoking, alcohol abuse, previous gastric surgery, glucocorticosteroid therapy...). The additive and cumulative effects of these risk factors have been advocated in male osteoporosis. <sup>(28)</sup>

Animal models have significantly contributed to understand the pathogenesis of bone loss induced by various clinical conditions. The orchidectomized rat (ORX) has been proposed to simulate osteoporosis due to hypogonadism <sup>(29-32)</sup>. Animal models of disuse osteoporosis have also received considerable attention (see review by Jee <sup>(33)</sup>). At the present time, non surgical methods such as hindlimb immobilisation by casting or bandaging <sup>(34)</sup>, tail suspension <sup>(35)</sup> or paralysis of a single muscle of the right hindlimb by the Botulinum neurotoxin <sup>(36)</sup> are favored because of the lack of surgical trauma or regional acceleratory phenomenon. <sup>(37)</sup>

The aim of the present study was to measure the regional variations of bone, lean and fat mass in a combined model associating ORX with a localized disuse induced by BTX. Subcutaneous injections of testosterone or risedronate (a third generation aminobisphosphorate) were used as counter-measures and their effects were investigated in a short time study (4 weeks after ORX and BTX). Dual energy X-ray absorptiometry (DXA), histomorphometry and X-ray microtomography (microCT) were used.

## **MATERIAL AND METHODS**

---

### **Animals**

Forty-eight males Wistar rats (Charles River, Cléon, France), aged 18-19 weeks and weighting  $507 \pm 33$ g were acclimated for 2 weeks to the local vivarium conditions (24°C and a 12-h/12-h light/dark cycle). Rats were given a standard laboratory food containing 0.8%

calcium (UAR; Villemoison sur Orge, France) and water *ad libitum*. Rats were randomised into 4 groups (12 animals per group).

On day 0, 36 rats were anaesthetized with halothane, orchidectomized bilaterally by scrotal incisions and ligation of testicular arteries. Incisions were closed with three clips. At the time of surgery, they were injected intramuscularly with *Clostridium Botulinum* type A neurotoxin (Laboratoire Transphyto, Clermont-Ferrand, France). Each animal received 2U of BTX dissolved in saline (0.4 ml) in the *quadriceps femoris* of the right hindlimb. They constituted the ORX-BTX animals. 12 rats were similarly anaesthetized, sham operated and received an injection of saline in the right hindlimb (0.4 ml). They served as control (SHAM group).

On day 1, countermeasures were initiated by subcutaneous administration during 4 weeks of either sodium risedronate (Procter and Gamble Pharmaceuticals), testosterone (water-soluble testosterone, Sigma T5035) or saline. The ORX-BTX rats were divided into 3 groups of 12 animals. The ORX-BTX-RISE group received risedronate (dissolved in saline) 5 µg/kg/day; 5 days/7. The ORX-BTX-TESTO group received testosterone (30 µg/day; 7 days/7). The ORX-BTX group received 0.5 ml of saline, 5 days/7.

Rats were weighted weekly. Four weeks after the beginning of the study, they were sacrificed with chloroform. At the time of sacrifice, whole body DXA measurements were made soon after euthanasia. Tibia and femur were dissected, defleshed and fixed in 70% ethanol with 1% acetic acid for 24hr at 4°C. Excized bones were measured again by DXA before other techniques.

### **Dual energy X-ray absorptiometry**

Measurements were done on a Hologic QDR 4500A (Hologic Inc., Waltham, MA) with a small animal software (release V8-26h). Before each series of measurements, a tissue calibration scan was performed with the Hologic phantom. Several parameters were obtained:

whole body bone mineral content (BMC), total lean and fat masses. Lean and fat masses were also determined on interactively drawn regions of interest: each right hind limb (R) and each left hind limb (L) (fig 1). BMC of the excised tibia and femur were measured using a proximal height resolution option with 0.0267 cm line spacing. Bones were placed in a plastic dish containing water at a constant depth for all measurements. The analysis of DXA scans was performed on the whole tibia, and in three regions of interest on each tibia centered on the proximal metaphysis (R1), diaphyseal shaft (R2), and distal metaphysis (R3). The lower limit of R1 was fixed at 20mm from the articular surfaces and the upper limits of R3 was fixed at the insertion of the fibula.

### **X-ray microtomography**

MicroCT was performed on the distal femur with a Skyscan 1072 X-ray computed microtomograph (Skyscan, Aartselaar, Belgium). Samples were fixed on brass stubs and analysed with a magnification of 26.95 (a pixel corresponding to 11.41  $\mu\text{m}$ ) with the fan beam mode. For each samples 219 section images were obtained every 11.41  $\mu\text{m}$  covering 2.5 mm, i.e., the cumulated height of the primary and secondary spongiosa. The 2D section images were stored in the .bmp format. After interactive segmentation, the 3D models were constructed from the stack of 2D images with a surface-rendering program (Ant, release 2.0.5, Skyscan, Aartselaar, Belgium). The 3D measurements were obtained with the CtAn software (release 2.5 - Skyscan - Aartselaar, Belgium). The volume of interest (VOI) was designed by drawing interactively polygons on the 2D gray images before reconstruction. Trabecular volume ( $BV/TV_{3D}$ ) and the structural model index (SMI) were calculated. SMI characterizes a 3D bone structure composed of a certain amount of plates and rods. The SMI has a value between 0 and 3. In an ideal plate model, the SMI value is 0, and in an ideal



cylindrical rod structure, the SMI is 3, independent of the physical dimensions of the structure.

Measurements on cortical bone were performed on a 2D section image at 4mm under the growth cartilage. Image was analysed with Image J software (release 1.34s-NIH-USA). After thresholding, three measurements were obtained: cortical area (Ct.Ar), average cortical thickness (Ct.Th) and outer diameter (B.Dm). Cross-sectional moment of inertia (CSMI) was calculated using the assumption that bones were roundly shaped <sup>(38)</sup>.

$$\text{CSMI} = (\pi/64) \times (\text{B.Dm}^4 - (\text{B.Dm} - 2\text{Ct.Th})^4)$$

### **Bone histomorphometry**

The fixed tibias were dehydrated in acetone and embedded undecalcified in methylmethacrylate. Sections (7 µm thick) were cut dry on a heavy-duty microtome equipped with tungsten carbide knives (Leica Polycut S, with 50° knives) and stained with a modified Goldner trichrome. Histomorphometric analysis was done on a Leica Quantimet Q570 image processor (Leica, France) equipped with a CCD camera (Sony 930). Bone sections were placed on an X-ray light box after equalization of light intensity. Digitized images of a complete section were stored in the grey image processor at a magnification of x6. After interactive thresholding, a binary image was displayed on the control monitor. The growth plate was identified interactively and the region of interest (comprising only the secondary spongiosa) was automatically recognized (1.5→3.5 mm from the growth plate). Artefacts created during the surgical and histotechnological steps were eliminated by automatic and interactive procedures. Trabeculae were disconnected from the endosteal surfaces by an interactive procedure as previously described <sup>(39)</sup>. Static and 2D microarchitectural histomorphometric measurements were obtained as previously reported <sup>(40)</sup> Trabecular Volume (BV/TV<sub>2D</sub>), Trabecular Thickness (Tb.Th), Trabecular Number (Tb.N), Trabecular

Separation (Tb.Sp), Free End Count (FEC), Node Count (NC), Star volume of marrow space ( $V_{m.space}^*$ ), Star volume of trabeculae ( $V_{Tb}^*$ ), Euler-Poincaré's Number (E), Kolmogorov's fractal dimension (D).

### **Statistical analysis**

Statistical study was performed using Systat statistical software, release 10.0 (SPSS inc. Chicago, IL). All data were expressed as mean  $\pm$  SEM. At each studied time, differences between the SHAM and different ORX-BTX subgroups were analyzed by ANOVA with the Fisher's Least Significant Difference post-hoc test. Data from left and right hindlimbs were compared using paired sample *t* test. Differences were considered as significant when  $p < 0.05$ .

## **RESULTS**

---

### ***DXA-whole body measurements (Fig. 2)***

#### ***Body BMC***

BMC of the whole body was significantly decreased in the ORX-BTX group (-7.2%  $p < 0.005$ ) and in the ORX-BTX-TESTO group (-5.2%  $p < 0.005$ ) versus SHAM. No difference could be observed after treatment with risedronate in the ORX-BTX-RISE group versus SHAM animals.

#### ***Lean body mass***

Lean body mass was considerably decreased with a significant difference in the ORX-BTX group (-14%  $p < 0.005$ ) and in the ORX-BTX-RISE group (-10.9%  $p < 0.005$ ) versus SHAM animals. No significant difference could be observed after treatment with testosterone in the ORX-BTX-TESTO animals compared with the SHAM group .

### *Fat body mass*

No significant change in fat body mass could be evidenced between ORX-BTX, ORX-BTX-RISE and ORX-BTX-TESTO versus SHAM.

### ***DXA - hindlimb measurements (Fig. 3)***

In the 3 groups ORX-BTX, ORX-BTX-RISE and ORX-BTX-TESTO, there was a significant loss of lean mass between the right (paralyzed hind limb) and left (intact hind limb). Lean mass was significantly decreased with a considerable difference of -20% on L and -43% on R in the 3 groups versus the comparable limbs in the SHAM group.

In the 3 groups ORX-BTX, ORX-BTX-RISE and ORX-BTX-TESTO, there was a significant increase of fat mass in the right (paralyzed hind limb) when compared to the left side. No significant difference for fat mass (L or R) was noted in the 3 groups versus SHAM.

### ***DXA of excised bones; comparison between R/L bones (table 1)***

The mean difference ( $\Delta$  in %) between the R and L bones was used to simplify comparisons. ( $\Delta = (R - L) * 100 / L$ ). When the whole bone was taken into consideration, a marked reduction of BMC was evidenced on the immobilized R side; this was verified for the tibia and femur, bone loss was in the same order of magnitude in the different groups. No R/L difference was noted in the SHAM group. When  $\Delta$  were calculated with the corresponding bones of SHAM animals, the influences of ORX and BTX were clearly evidenced. Also, the additive deleterious action of the two factors was highly shown in the ORX-BTX group and the bone loss was similar for the tibia and femur. In rats treated with risedronate, the bisphosphonate prevented bone loss excepted in the R tibia where  $\Delta$ BMC reached significance. Bone loss prevention by testosterone was ineffective since bone gain was minimal on the left side ( $\Delta = +5.6\%$  vs. ORX-BTX group,  $p = 0.15$ ) and on the right side ( $\Delta = +3.8\%$  vs. ORX-BTX

group,  $p = 0.36$ ). When the subregions of the tibia were considered, bone loss was hereagain found to be maximized when the conjoint actions of ORX and BTX acted on the right side with a considerable bone loss of -33.5% in the R1 region of interest in the ORX-BTX group. The difference was also highly significant for the R2 region (mostly cortical) ( $\Delta = -20.8\%$ ) and the R/L difference was noted, confirming the additional effect of disuse and hormone deprivation. On the other hand, no difference was observed with SHAM rats and no R/L difference could be evidenced for the R3 region (exclusively cortical). Animals which had received risedronate had a complete preservation of bone mass in the R1 region on the right bone and presented a +9.0% increase on the left side (with an highly significant difference between the two sides,  $p < 0.001$ ). Interestingly, the bisphosphonate had little effect on the R2 region since the values were slightly improved, but did not reached significance, when compared to the ORX-BTX group. The R/L difference was not significant. No effect was observable on R3.

Testosterone slightly improved R1 values in the ORX-BTX-TESTO group but bone loss remained dramatically reduced on the right side. In the R2 and R3 regions, testosterone appeared not significantly effective on bone loss.

### ***Histomorphometric analysis (table 2)***

In the ORX-BTX group, BV/TV and Tb.N were significantly decreased ( $p < 0.001$ ) and conversely, Tb.Sp increased ( $p < 0.005$ ). No significant R/L difference was evidenced in this group. Tb.Th was not modified on the L-side but decreased on R-side submitted to both disuse and hormonal deprivation ( $p < 0.05$ ). Microarchitectural changes in this group indicated the occurrence of trabecular perforation and removal of complete trabeculae evidenced by an increased of  $V^*_{m.space}$  ( $p < 0.001$ ), a decreased of NC ( $p < 0.001$ ), FEC ( $p < 0.001$ ) and  $V^*_{trab}$  (only on the R-side,  $p < 0.05$ ). The fractal dimension D was significantly reduced on the two

sides ( $p < 0.001$ ) and confirmed the loss of complexity and connectivity of the trabecular network.

In the ORX-BTX-RISE group, risedronate appeared effective in preserving bone mass since BV/TV, Tb.SP were not modified when compared to SHAM; Tb.N was over-compensated on the two hindlimb ( $p < 0.005$ ) but trabecular thickness remained at lower values than in SHAM animals. No significant R/L difference was evidenced. All other parameters values were improved and significantly differed from those of the ORX-BTX group ( $p < 0.005$ ). All the 2D microarchitectural parameters were indicated that trabecular architecture was preserved by thin and more numerous trabeculae with a lower  $V_{\text{trab}}^*$  ( $p < 0.05$  on the L side).

In the ORX-BTX-TESTO group, BV/TV and Tb.N remained significantly decreased ( $p < 0.001$ ) and Tb.Sp was not modified when compared to SHAM values. Tb.Th and Tb.N from the L side were significantly increased and Tb.Sp from both L and R side decreased when compared to ORX-BTX. It is noticeable that trabecular thickness was not different from control animals. The architectural parameters were still altered and exhibited a loss of trabeculae with increased separation and loss of connectivity vs. SHAM, the difference did not reach significance when compared with the ORX-BTX group except  $V_{\text{trab}}^*$  from the R side ( $p < 0.05$ ). In both L and R side, it appeared that testosterone treatment was significantly less effective than risedronate except for trabecular thickness.

### ***MicroCT analysis***

3D images reconstructions performed by microCT on the right side of the tibia showed the bone trabecular loss in ORX-BTX compared to SHAM (Fig. 4A and B). Trabecular network was preserved in ORX-BTX-RISE group (Fig. 4C) but not in ORX-BTX-TESTO group (Fig. 4D). These results were confirmed by 3D measurements summarized in table 2. BV/TV<sub>3D</sub> decreased and SMI increased significantly in the ORX-BTX group versus SHAM and the

values were maximized on R side. The bisphosphonate preserved bone mass and microarchitecture since no significant difference was observed with SHAM animals and the difference was highly significant with the ORX-BTX-RISE group. No significant differences between R/L were found in this group. In the ORX-BTX-TESTO group, microCT confirmed that testosterone was ineffective in preserving bone mass and architecture; the R/L difference was significant. SMI increased, emphasizing the increased conversion of trabeculae from plates to rods.

When cortical parameters were considered (Table 2, Fig. 5), it was noticeable that no significant change in outer diameter could be evidenced between the 4 groups. Ct.Ar, Ct.Th and CSMI were decreased on the R side in the ORX\_BT X group. On the L side, only Ct.Ar and CSMI were significantly decreased. The R/L difference was significant for the 3 parameters: Ct.Ar, Ct.Th and CSMI. Risedronate preserved cortical bone on the L side but only slightly improved Ct.Ar, Ct.Th and CSMI values from the R side as these values remained lower compared to SHAM. Testosterone was ineffective in preserving cortical bone. Ct.Ar, Ct.Th and CSMI were also found significantly lower compared to those in SHAM.

## **DISCUSSION**

---

Several factors are known to control bone mass in humans and animals. Genetic influences, nutritional factors (such as protein or calcium intake), physical activity and endocrine status have been shown to play key roles in human <sup>(41)</sup>. Changes in body composition (lean and fat mass) and BMC have been repeatedly reported being associated with a decrease in blood estrogen level in women <sup>(13,42)</sup> In men, a decreased androgen level is associated with decreased lean body mass; an increase in fat mass is associated with

aging<sup>(8)</sup>. Acquired hypogonadism has also been found to induce similar modifications<sup>(11)</sup>. In hypogonadic men, the increase in bone density and lean body mass during testosterone therapy have been reported in patients whose age ranged from 22 to 69 years<sup>(12)</sup>. Similarly, testosterone was found to reduce bone remodeling and increase muscle mass in castrated animals in hypogonadic patients.<sup>(43)</sup>

The aged male rat appears a useful model for studying the age-related changes in body composition, bone or muscle mass<sup>(44,45)</sup>. The ORX rat model has been found appropriate for investigating the bone, lean and fat mass changes induced by androgen deficiency<sup>(46)</sup>. DXA is a sensitive and reproducible technique to measure bone loss in small laboratory animals. In the aged rat, it was previously reported that ORX influenced BMC, lean mass but had no effect on fat mass<sup>(45,46)</sup>. Testosterone appeared to compensate the lean mass, but its action was not sufficient to be visible on the right or left hind limb when compared to SHAM animals. A significant difference exists between the two hind limb: risedronate or testosterone have no effect on lean mass in each limb separate.

Risedronate is a third generation aminobisphosphonate with potent antiresorptive activity. It was found to inhibit bone loss due to hormone deprivation, and has proven highly effective in patients with osteoporosis.<sup>(47,48)</sup>

Injection of BTX only in the right hindlimb reduced body BMC. Testosterone had no effect on whole body bone loss. Risedronate compensated entirely the whole body bone loss. The results were more intensive and more precocious on the whole body when we compared with the experimentation with only ORX<sup>(46)</sup> and on the right limb, immobilized by BTX. The effects of ORX and BTX was cumulative on bone loss and lean mass loss.

In the excised bone (Fig 6) the effect of ORX and BTX was cumulative on bone loss in ORX-BTX group on the immobilized (right) side. Risedronate did compensate the loss of BMC in the

non-immobilized side, but the dose is not sufficient to compensate the great loss in the immobilized side.

Bone loss is also associated with an alteration of bone architecture, which can be appreciated by histomorphometric methods<sup>(36,39,40)</sup>. The World Health Organisation, Guidelines for preclinical evaluation and clinical trials in osteoporosis (WHO) considered that the histomorphometric technique remains the “gold standard” to quantify bone loss in animals<sup>(49)</sup>. ORX-induced bone loss is due to the removal of complete trabeculae by an increased osteoclastic resorption as evidenced by decreased Tb.N and increased  $V_{m.space}^*$  while the thickness of trabeculae is not altered (Tb.Th and  $V_{tb}^*$  remain constant)<sup>(50)</sup>.

In this study, we found that the effects of ORX and BTX-induced paralysis were cumulative on trabecular bone since BV/TV and Tb.N were considerably decreased on the right side submitted to both deleterious actions. We recently showed that serum TRAcP levels (reflecting osteoclast activity) were higher in ORX-BTX compared to ORX corresponding to a greater bone resorption and explaining the maximal loss in the R limb<sup>(51)</sup>. Risedronate compensates or overcompensates BV/TV and Tb.N but not Tb.Th and  $V_{tb}^*$ . Testosterone seems to have an action on the two parameters Tb.Th and  $V_{tb}^*$ .

The increase of SMI in the ORX-BTX group, confirmed the increased osteoclastic activity leading to a marked conversion of plates into pillars. This effect was fully abolished by risedronate but testosterone failed to preserve bone mass in the metaphyseal region. Finally, we showed that risedronate was effective to preserve cortical bone mass and mechanical properties in bone loss induced by ORX but unable to prevent cortical bone changes in bone loss induced by the combination of ORX and disuse. Similar results were observed in a long term disuse model in dogs in which risedronate failed to prevent cortical thinning and altered mechanical properties<sup>(52)</sup>.



In summary, a massive bone loss can be generated in the male rat by using a non-surgical immobilization of one hindlimb combined with an hormone deprivation induced by castration. An interesting advantage of the model is that disuse is localized on one side, the animal is its own control. It has been shown that the effect of hormonal deprivation and immobilization are additive after 4 weeks. <sup>(50)</sup> This combined model is easy to handle and appears very suitable to evaluate pharmacological compounds since the bone loss occurs rapidly. We have shown the early and protective effects of risedronate on the trabecular bone mass and bone architecture.

**Table 1: BMC comparison between left and right bones**

	SHAM	ORX-BTX	ORX-BTX-RISE	ORX-BTX-TESTO
<i>intragroup comparison of the difference between left and right (in %)</i>				
Δ tibia	0.5 ± 0.7	-8.7 ± 1.4 <sup>a</sup>	-5.5 ± 0.9 <sup>a</sup>	-10.2 ± 1.4 <sup>a</sup>
Δ femur	0.5 ± 0.9	-8.3 ± 2.4 <sup>a</sup>	-4.4 ± 1.1 <sup>a</sup>	-8.3 ± 1.5 <sup>a</sup>
<i>intergroup comparison of the differences of total BMC with SHAM animals (in %)</i>				
Δ Left tibia		-11.5 <sup>a</sup>	-3.7	-6.6 <sup>a</sup>
Δ Right tibia		-19.8 <sup>a</sup>	-9.4 <sup>a</sup>	-16.0 <sup>a</sup>
Δ Left femur		-11.6 <sup>a</sup>	-2.4	-6.6
Δ Right femur		-19.5 <sup>a</sup>	-6.9	-14.0 <sup>a</sup>
<i>intergroup comparison of the differences of regional tibia BMC with SHAM animals (in %)</i>				
Δ Left R1		-11.2 <sup>a</sup>	+9.0 <sup>a</sup>	-9.1 <sup>a</sup>
Δ Left R2		-15.3 <sup>a</sup>	-14.8 <sup>a</sup>	-9.0 <sup>a</sup>
Δ Left R3		-5.5	+0.7	+0.7
Δ Right R1		-33.5 <sup>a</sup>	-1.3	-27.9 <sup>a</sup>
Δ Right R2		-20.8 <sup>a</sup>	-17.2 <sup>a</sup>	-17.6 <sup>a</sup>
Δ Right R3		-3.0	-4.6	-3.0

<sup>a</sup> p < 0.05 vs. SHAM

**Table 2: Histomorphometry and MicroCT data**

	SHAM		ORX-BTX		ORX-BTX-RISE		ORX-BTX-TESTO	
	Left	Right	Left	Right	Left	Right	Left	Right
Bone 2D histomorphometry parameters								
BV/TV (%)	12.8 ± 0.8	13.2 ± 1.3	6.0 ± 1.2 <sup>a</sup>	4.2 ± 0.8 <sup>a</sup>	15.6 ± 0.4 <sup>b</sup>	15.5 ± 0.6 <sup>b</sup>	8.44 ± 0.94 <sup>a,c</sup>	6.47 ± 1.38 <sup>a,c</sup>
Tb.Th (µm)	66.3 ± 1.2	68.6 ± 1.6	62.7 ± 3.4	58.0 ± 2.2 <sup>a</sup>	59.1 ± 1.1 <sup>a</sup>	59.0 ± 2.4 <sup>a</sup>	68.5 ± 1.1 <sup>b,c</sup>	66.7 ± 2.2 <sup>c</sup>
Tb.N (/mm)	1.9 ± 0.1	1.9 ± 0.2	0.9 ± 0.2 <sup>a</sup>	0.7 ± 0.1 <sup>a</sup>	2.6 ± 0.04 <sup>a,b</sup>	2.6 ± 0.07 <sup>a,b</sup>	1.2 ± 0.1 <sup>a,b,c</sup>	1.0 ± 0.2 <sup>a,c</sup>
Tb.Sp (µm)	473 ± 35	495 ± 46	1542 ± 340 <sup>a</sup>	2824 ± 856 <sup>a</sup>	321 ± 6 <sup>b</sup>	322 ± 9 <sup>b</sup>	823 ± 72 <sup>b</sup>	1680 ± 358 <sup>b</sup>
E	4.36 ± 0.23	4.16 ± 0.24	2.62 ± 0.41 <sup>a</sup>	1.92 ± 0.36 <sup>a</sup>	6.30 ± 0.41 <sup>a,b</sup>	6.58 ± 0.37 <sup>a,b</sup>	2.79 ± 0.03 <sup>a,c</sup>	2.25 ± 0.4 <sup>a,c</sup>
NC	1.4 ± 0.2	1.3 ± 0.2	0.6 ± 0.1 <sup>a</sup>	0.3 ± 0.1 <sup>a</sup>	1.8 ± 0.1 <sup>b</sup>	1.8 ± 0.2 <sup>b</sup>	0.8 ± 0.1 <sup>a,c</sup>	0.7 ± 0.2 <sup>a,c</sup>
FEC	6.4 ± 0.4	6.2 ± 0.6	3.3 ± 0.6 <sup>a</sup>	2.2 ± 0.5 <sup>a</sup>	8.9 ± 0.4 <sup>a,b</sup>	9.3 ± 0.5 <sup>a,b</sup>	4.1 ± 0.5 <sup>a,c</sup>	3.0 ± 0.6 <sup>a,c</sup>
V <sup>*<sub>m.space</sub></sup> (µm <sup>3</sup> )	7.7 ± 1.9	9.7 ± 2.0	32.8 ± 6.6 <sup>a</sup>	51.0 ± 10.4 <sup>a</sup>	2.9 ± 0.5 <sup>b</sup>	2.9 ± 0.6 <sup>b</sup>	24.9 ± 5.0 <sup>a,c</sup>	45.4 ± 9.8 <sup>a,c</sup>
V <sup>*<sub>trab</sub></sup> (µm <sup>3</sup> )	0.031 ± 0.003	0.029 ± 0.003	0.024 ± 0.003	0.017 ± 0.003 <sup>a</sup>	0.023 ± 0.002 <sup>a</sup>	0.022 ± 0.002	0.029 ± 0.002	0.031 ± 0.003 <sup>b,c</sup>
D	1.36 ± 0.03	1.34 ± 0.03	1.09 ± 0.05 <sup>a</sup>	0.94 ± 0.08 <sup>a</sup>	1.42 ± 0.02 <sup>b</sup>	1.43 ± 0.02 <sup>b</sup>	1.2 ± 0.05 <sup>a,c</sup>	1.11 ± 0.05 <sup>a,b,c</sup>
MicroCT measurements								
BV/TV <sub>3D</sub> (%)	21.0 ± 1.2	21.5 ± 1.2	12.4 ± 1.4 <sup>a</sup>	8.7 ± 1.5 <sup>a</sup>	21.9 ± 1.6 <sup>b</sup>	20.8 ± 1.3 <sup>b</sup>	13.3 ± 1.1 <sup>a,c</sup>	9.1 ± 0.9 <sup>a,c</sup>
SMI	1.33 ± 0.05	1.31 ± 0.04	1.72 ± 0.06 <sup>a</sup>	1.96 ± 0.08 <sup>a</sup>	1.36 ± 0.06 <sup>b</sup>	1.45 ± 0.06 <sup>b</sup>	1.60 ± 0.05 <sup>a,c</sup>	1.83 ± 0.04 <sup>a,c</sup>
Ct.Ar (mm <sup>2</sup> )	67.4 ± 2.0	68.7 ± 1.5	63.3 ± 1.2 <sup>a</sup>	57.8 ± 1.2 <sup>a</sup>	65.6 ± 0.8	62.5 ± 1.1 <sup>a,b</sup>	51.6 ± 1.3 <sup>a,b,c</sup>	54.1 ± 1.0 <sup>a,b,c</sup>
Ct.Th (µm)	64.7 ± 1.1	66.4 ± 1.1	63.5 ± 1.4	57.2 ± 1.4 <sup>a</sup>	64.8 ± 1.2	61.2 ± 1.3 <sup>a,b</sup>	58.9 ± 1.4 <sup>a,b,c</sup>	49.9 ± 1.1 <sup>a,b,c</sup>
B.Dm (mm)	1.59 ± 0.04	1.58 ± 0.04	1.52 ± 0.03	1.50 ± 0.03	1.54 ± 0.03	1.54 ± 0.03	1.52 ± 0.03	1.50 ± 0.03
CSMI (×10 <sup>-2</sup> )	9.2 ± 0.8	9.1 ± 0.7	7.7 ± 0.4 <sup>a</sup>	6.8 ± 0.4 <sup>a</sup>	8.2 ± 0.4	7.8 ± 0.5 <sup>a</sup>	6.8 ± 0.4 <sup>a,c</sup>	6.0 ± 0.3 <sup>a,c</sup>

<sup>a</sup> p < 0.05 vs. SHAM, <sup>b</sup> p < 0.05 vs. ORX-BTX, <sup>c</sup> p < 0.05 vs. ORX-BTX-RISE  
The gray boxes indicate a significant difference vs. left with p < 0.05

## ACKNOWLEDGMENTS

---

Authors are greatly indebted to P. Legras and J. Leroux for their help with the animal care and to G. Brossard and N. Gaborit for their help with X-ray microCT. This work was supported by funds from “Pays de la Loire” – Axe Biomatériaux and INSERM. They also express many thanks to Roger J. Phipps (Procter and Gamble Pharmaceuticals Inc.) for having reviewed the manuscript.

## LEGENDS OF FIGURES:

---

Figure 1: Whole body image of a wistar rat analysed with the Hologic QDR 4500A. Note the marked difference in intensity between the right (R) and left (L) femur and tibia.

Figure 2: Whole body BMC and lean body mass from DXA measurements.

Figure 3: Lean and fat mass from DXA hindlimb measurements.

#  $p < 0.0001$ , \*  $p < 0.0001$

Figure 4: X-ray microCT 3D reconstructions of the right inner side of the tibia in: SHAM (A), ORX-BTX (B), ORX-BTX-RISE (C), ORX-BTX-TESTO (D).

Figure 5: X-ray microCT 2D section images from the right inner side of the tibia in: SHAM (A), ORX-BTX (B), ORX-BTX-RISE (C), ORX-BTX-TESTO (D).

## REFERENCES

---

1. Kanis JA 1993 The incidence of hip fracture in Europe. *Osteoporos Int* **3 S1**:10-15.
2. Lau EM, Cooper C 2001 Risk factors for osteoporosis in Europe. *J Bone Miner Metab* **19**:142-5.
3. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ 1996 The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. *J Bone Miner Res* **11**:1010-8.
4. Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. *J Bone Miner Res* **8**:1227-1233.
5. Legrand E, Hedde C, Gallois Y, Degasne I, Boux de Casson F, Mathieu E, Baslé MF, Chappard D, Audran M 2001 Osteoporosis in men: a potential role for the sex hormone binding globulin. *Bone* **29**:90-5.
6. Kaufman JM, Vermeulen A 1997 Declining gonadal function in elderly men. *Baillieres Clin Endocrinol Metab* **11**:289-309.
7. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL 1999 Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. *J Clin Endocrinol Metab* **84**:2647-2653.
8. Vermeulen A, Goemaere S, Kaufman JM 1999 Testosterone, body composition and aging. *J Endocrinol Invest* **22**:110-116.
9. van-den-Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW 2000 Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. *J Clin Endocrinol Metab* **85**:3276-3282.
10. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston S, Reeve J, Reid DM, Russell RGG, Stevenson JC 1998 Management of male osteoporosis: report of the UK consensus group. *Q J Med* **91**:71-92.
11. Grinspoon S, Corcoran C, Lee K, Burrows B, Hubbard J, Katznelson L, Walsh M, Guccione A, Cannan J, Heller H, Basgoz N, Klibanski A 1996 Loss of lean body and


- muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. *J Clin Endocrinol Metab* **81**:4051-4058.
12. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A 1996 Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab* **81**:4358-4365.
  13. Reid IR, Ames R, Evans MC, Sharp S, Gamble G, France JT, Lim TMT, Kundy TF 1992 Determinants of total body and regional bone mineral density in normal post-menopausal women - a key role for fat mass. *J Clin Endocrinol Metab* **75**:45-51.
  14. Reid IR, Evans MC, Ames R 1994 Volumetric bone density of the lumbar spine is related to fat mass but not to lean mass in normal post-menopausal women. *Osteoporos Int* **4**:362-367.
  15. Edelstein SL, Barrett-Connor E 1993 Relation between body size and bone mineral density in elderly men and women. *Am J Epidemiol* **138**:160-169.
  16. Lindsay R 1992 The growing problem of osteoporosis. *Osteoporos Int* **2**:267-8.
  17. Khosla S, Atkinson EJ, Riggs BL, Melton LJI 1996 Relationship between body composition and bone mass in women. *J Bone Miner Res* **11**: 857-863.
  18. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty-G. 2000 Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. *Cell* **100**:197-207.
  19. Taaffe DR, Cauley JA, Danielson M, Nevitt MC, Lang TF, Bauer DC, Harris TB 2001 Race and sex effects on the association between muscle strength, soft tissue, and bone mineral density in healthy elders: the Health, Aging, and Body Composition Study. *J Bone Miner Res* **16**:1343-52.
  20. Uusi-Rasi K, Sievanen H, Pasanen M, Oja P, Vuori I 2002 Association of physical activity and calcium intake with the maintenance of bone mass in premenopausal women. *Osteoporos Int* **13**:211-7.
  21. Kontogianni MD, Dafni UG, Routsias JG, Skopouli FN 2004 Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. *J Bone Miner Res* **19**:546-51.
  22. Minaire P, Neunier P, Edouard C, Bernard J, Courpron P, Bourret J 1974 Quantitative histological data on disuse osteoporosis: comparison with biological data. *Calcif Tissue Res* **17**:57-73.

- HAL author manuscript inserm-00259382, version 1
23. Kannus P, Jarvinen M, Sievanen H, Jarvinen TA, Oja P, Vuori I 1994 Reduced bone mineral density in men with a previous femur fracture. *J Bone Miner Res* **9**:1729-36.
  24. Chappard D, Alexandre C, Vico L, Palle S, Riffat G 1986 Amputation-induced osteoporosis: a new model to explore the effects of weightlessness on the human skeleton. In: *physiology IS-EeS* (ed.) 2nd Int Conference on Space Physiology. ESA Publ. Div., Noordwijk, The Netherlands, pp 115-118.
  25. Hodkinson HM, Brain AT 1967 Unilateral osteoporosis in longstanding hemiplegia in the elderly. *J Am Geriatr Soc* **15**:59-64.
  26. Prior JC, Barr SI, Chow R, Faulkner RA 1996 Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis. *CMAJ* **155**:940-4.
  27. Gregg EW, Pereira MA, Caspersen CJ 2000 Physical activity, falls, and fractures among older adults: a review of the epidemiologic evidence. *J Am Geriatr Soc* **48**:883-93.
  28. Legrand E, Chappard D, Insalaco P, Simon Y, Baslé MF, Audran M 2002 Trabecular bone microarchitecture is related to clinical risk factors in osteoporosis in men (abstract). *Osteoporos Int* **13S**:45.
  29. Gurkan L, Ekeland A, Gautvik KM, Langeland N, Ronningen H, Solheim LF 1986 Bone changes after castration in rats: a model of osteoporosis. *Acta Orthop Scand* **57**:67-70.
  30. Wink CS, Felts WJL 1980 Effects of castration on bone structure of male rats. A model of osteoporosis. *Calcif Tissue Int* **32**:77-82.
  31. Verhas M, Schoutens A, L'hermite-Baleriaux M, Dourov N, Verschaeren A, Mone M, Heilporn A 1986 The effect of orchidectomy on bone metabolism in aging rats. *Calcif Tissue Int* **39**:74-77.
  32. Vanderschueren D, Jans I, Van-Herck E, Moermans K, Verhaeghe J, Bouillon R 1994 Time-related increase of biochemical markers of bone turnover in androgen-deficient male rats. *Bone Miner* **26**:123-131.
  33. Jee WSS, Ma Y 1999 Animal models of immobilization osteopenia. *Morphologie* **83**:25-34.
  34. Ijiri K, Ma, Ye, Jee, W.S.S., Et al. 1995 Adaptation of non-growing former epiphyses, metaphyseal bones to aging, immobilization in rat. *Bone* **17**:207S-212S.



35. Wronski TJ, Morey-Holton ER 1987 Skeletal response to stimulated weightlessness: a comparison of suspension techniques. *Aviation Space Env Med* **58**.
36. Chappard D, Chennebault A, Moreau MF, Legrand E, Audran M, Baslé MF 2001 Texture analysis of X-ray radiographs is a more reliable descriptor of bone loss than mineral content in a rat model of localized disuse induced by the *Clostridium botulinum* toxin. *Bone*:in press.
37. Frost HM 1983 The regional acceleratory phenomenon. A review. *Henry Ford Hosp Med J* **31**:3-9.
38. Fazzalari NL, Parkinson IH 1998 Femoral trabecular bone of osteoarthritic and normal subjects in an age and sex matched group. *Osteoarthritis Cartilage* **6**:377-82.
39. Libouban H, Moreau MF, Baslé MF, Audran M, Chappard D 2001 Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight and morphometric indices for bone evaluation in an animal model of male osteoporosis (the orchidectomized rat). *Calcif Tissue Int* **68**:31-37.
40. Chappard D, Legrand E, Pascaretti C, Basle MF, Audran M 1999 Comparison of eight histomorphometric methods for measuring trabecular bone architecture by image analysis on histological sections. *Microsc Res Tech* **45**:303-12.
41. Rizzoli R, Bonjour JP 1999 Determinants of peak bone mass and mechanisms of bone loss. *Osteoporos Int* **9-S2**:17-23.
42. Lindsay R, Cosman F, Nieves J 1993 Estrogen: effects and actions in osteoporosis. *Osteoporos Int* **3-S1**:150-152.
43. Bross R, Casaburi R, Storer TW, Bhasin S 1998 Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. *Baillieres Clin Endocrinol Metab* **12**: 365-378.
44. Vanderschueren D, Van Herck E, Schot P, Rush E, Einhorn T, Geusens P, Bouillon R 1993 The aged male rat as a model for human osteoporosis: evaluation by nondestructive measurements and biomechanical testing. *Calcif Tissue Int* **53**:342-347.
45. Vanderschueren D, Vandenput L, Boonen S, Van H, E., Swinnen JV, Bouillon R 2000 An aged rat model of partial androgen deficiency: prevention of both loss of bone and lean body mass by low, dose androgen replacement. *Endocrinology* **141**:1642-1647.

- HAL author manuscript inserm-00259382, version 1
46. Moreau MF, Libouban H, Legrand E, Baslé MF, Chappard D 2001 Lean, fat and bone masses are influenced by orchidectomy in the rat. A densitometric X-ray absorptiometric study. *J Musculoskel Neuron Interact* **1**:209-213.
  47. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. *N Engl J Med* **344**:333-40.
  48. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. *Osteoporos Int* **11**:83-91.
  49. 1998 World Health Organization. Guidelines for preclinical evaluation and clinical trials in osteoporosis., Geneva.
  50. Libouban H, Moreau MF, Legrand E, Audran M, Basle MF, Chappard D 2002 Comparison of histomorphometric descriptors of bone architecture with dual-energy X-ray absorptiometry for assessing bone loss in the orchidectomized rat. *Osteoporos Int* **13**:422-8.
  51. Blouin S., Gallois Y., Moreau M.F., Baslé M.F., D. C 2006 Disuse and orchidectomy have additional effects on bone loss in the aged male rat. *Osteoporosis Int*:accepted for publication.
  52. Li CY, Price C, Delisser K, Nasser P, Laudier D, Clement M, Jepsen KJ, Schaffler MB 2005 Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. *J Bone Miner Res* **20**:117-24.






Figure 2.




Figure 3.

